Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shinji Sone is active.

Publication


Featured researches published by Shinji Sone.


Transfusion and Apheresis Science | 2015

Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness

Yuko Mishima; Nelson H. Tsuno; Mika Matsuhashi; Tetsuichi Yoshizato; Tomohiko Sato; Toshiyuki Ikeda; Naoko Watanabe-Okochi; Yutaka Nagura; Shinji Sone; Mineo Kurokawa; Hitoshi Okazaki

BACKGROUND Multiple platelet exposure induces anti-HLA and/or anti-HPA antibody production, which may cause platelet transfusion refractoriness (PTR). In Japan, the universal pre-storage leukocyte reduction (ULR) was fully implemented since 2006, but prior to ULR, in our institution, leukocyte reduction filters were routinely used at the bedside (bedside leukoreduction, BSLR) for all onco-hematological patients receiving multiple platelet transfusions. OBJECTIVE We retrospectively compared patients receiving platelet transfusions in the era of ULR with those of BSLR era. MATERIALS AND METHODS Patients of the BSLR group (409 cases) and the ULR group (586 cases) were compared in terms of alloimmunization and immunological PTR. The clinico-pathological features, including gender, history of pregnancy, number of exposed transfusion donors, periods of transfusion, and prior stem cell transplantation were compared, and the risk factors of alloimmunization were determined. RESULTS The antibody detection rate was significantly higher in the ULR compared to BSLR group (8.7% vs. 5.4%), as well as the immunological PTR rate (7.3% vs. 3.2%). By the multivariate analysis, female gender and the number of platelet donor exposure, but not universal leukoreduction or transfusion period, were found to be the risk factors strongly associated with alloantibody formation. CONCLUSION Although ULR may be superior to BSLR in terms of preventing non-hemolytic transfusion reactions, BSLR was found to be as effective as ULR in terms of preventing platelet alloimmunization and refractoriness. Thus, BSLR should be actively indicated as a realistic alternative in developing countries, before the universal leukoreduction is fully implemented.


Transfusion and Apheresis Science | 2013

The current status of autologous blood transfusion in Japan--the importance of pre-deposit autologous blood donation program and the needs to achieve patient blood management.

Nelson H. Tsuno; Yutaka Nagura; Michiru Kawabata; Mika Matsuhashi; Shinji Sone; Toshiyuki Ikeda; Naoko Okochi; Koki Takahashi

BACKGROUND Autologous blood transfusion (ABT) is currently considered the safest transfusion, since the risks of allogeneic immunological reaction and viral transmission are theoretically null. Although its use has declined in Western countries in the recent decade, it has been progressively expanded in Japan. With the widening of the concept of patient blood management (PBM), which aims to prevent the harmful adverse effects of the exposure to allogeneic blood, the importance of the ABT has once again gained interest. STUDY DESIGN AND METHODS Here, we retrospectively analyzed the cases pre-depositing autologous blood for an elective surgery in the period of January 2000 to December 2010 in our hospital, where a pre-deposit autologous blood donation (PAD) program has been established in 2006, in an attempt to analyze the improvements achieved, and the problems remaining to achieve patient blood management. RESULTS The PAD program contributed for the further improvement of ABT, and the number of participating patients increased, especially in the period 2002-2003, when the idea of PAD program implementation came out. By simple extrapolation of the ABT data to allogeneic blood, ABT was found to be superior in terms of cost-effectiveness. However, problems such as the high wastage rate, and the inappropriate transfusion triggers remain to be solved. CONCLUSION ABT plays the central role in PBM, but to achieve the real PBM, there is need to indicate ABT appropriately, according to the individual needs, and use it adequately, without discarding. Our present data reflect the present status of the ABT performance in Japan, and will serve as the basis for the development of strategies to achieve safe and appropriate performance of ABT, and consequently, achieve PBM.


Transfusion | 2014

The role of alloantibodies against human platelet antigen-15 in multiply platelet transfused patients

Mika Matsuhashi; Nelson H. Tsuno; Shinji Sone; Yuko Mishima; Yutaka Nagura; Naoko Watanabe-Okochi; Toshiyuki Ikeda; Koichi Kashiwase; Shinya Fukuda; Takayuki Iriyama; Hironobu Hyodo; Takahiro Yamashita; Yoshimasa Kamei; Shunya Arai; Mutsuhiko Minami; Tomoyuku Fujii; Mineo Kurokawa; Minoru Tozuka; Koki Takahashi; Sentot Santoso

Several studies have documented the role of antibodies against human platelet (PLT) antigen (HPA)‐15 in alloimmune‐mediated thrombocytopenia including neonatal alloimmune thrombocytopenia, PLT transfusion refractoriness (PTR), and posttransfusion purpura in Caucasian persons. However, the relevance of anti‐HPA‐15 in PTR among the Japanese population is still unclear.


Journal of Obstetrics and Gynaecology Research | 2014

Safety and efficacy of preoperative autologous blood donation for high-risk pregnant women: experience of a large university hospital in Japan.

Yasuhiro Yamamoto; Takahiro Yamashita; Nelson H. Tsuno; Takeshi Nagamatsu; Naoko Okochi; Hironobu Hyodo; Toshiyuki Ikeda; Michiru Kawabata; Yoshimasa Kamei; Yutaka Nagura; Shinji Sone; Tomoyuki Fujii; Koki Takahashi; Shiro Kozuma

Preoperative autologous blood donation (PAD) has the advantages over allogeneic blood transfusion of theoretically no risk of viral infection and alloimmunization. However, there are some concerns regarding PAD in pregnant women, as they sometimes become anemic and adverse effects such as low blood pressure could be harmful to fetuses. In our hospital, the PAD program was implemented in 2006 and has been used in pregnant women at high risk of massive hemorrhage. In this study, the safety of PAD in pregnant women and its efficacy for avoiding allogeneic blood transfusion were investigated.


Journal of Viral Hepatitis | 2018

Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals

Hiromi Hikita; Masaya Sato; Mamiko Sato; Yoko Soroida; Tamaki Kobayashi; Hiroaki Gotoh; Tomomi Iwai; Ryo Nakagomi; Ryosuke Tateishi; Takako Komuro; Shinji Sone; Kazuhiko Koike; Yutaka Yatomi; Hitoshi Ikeda

Perihepatic lymph node enlargement (PLNE) which has been shown to be negatively associated with hepatocellular carcinoma (HCC) occurrence is frequently observed in chronic liver disease; however, changes in the state of perihepatic lymph nodes after eradication of hepatitis C virus (HCV) have not been investigated yet. We aimed to evaluate this issue. We enrolled 472 patients with chronic HCV infection who achieved viral eradication with direct‐acting antivirals (DAA). We investigated whether the status of perihepatic lymph nodes changed before and after HCV eradication (primary endpoint). We also evaluated the association between PLNE and clinical findings such as liver fibrosis or hepatocellular injury before HCV eradication (secondary endpoint). Perihepatic lymph node enlargement was detected in 164 of 472 (34.7%) patients before DAA treatment. Surprisingly, disappearance of PLNE was observed in 23.8% (39 patients) of all PLNE‐positive patients after eradication of HCV. Disappearance of PLNE was not associated with baseline clinical parameters or changing rates of clinical findings before and after DAA treatment. At baseline, presence of PLNE was significantly associated with a lower serum HCV‐RNA level (P = .03), a higher serum AST level (P = .004) and a higher ALT level (P < .001) after adjustment for sex and age. In conclusion, PLNEs became undetectable after DAA treatment in 23.8% of PLNE‐positive patients. Further study with a longer follow‐up period is needed to clarify the clinical importance of this phenomenon especially in relationship with the risk of HCC development.


Journal of Clinical Biochemistry and Nutrition | 2017

Evaluation of human nonmercaptalbumin as a marker for oxidative stress and its association with various parameters in blood

Rie Masudo; Keiko Yasukawa; Takahiro Nojiri; Naoyuki Yoshikawa; Hironori Shimosaka; Shinji Sone; Yumiko Oike; Akemi Ugawa; Tsutomu Yamazaki; Kentaro Shimokado; Yutaka Yatomi; Hitoshi Ikeda

Oxidative status of albumin was not a useful biomarker for oxidative stress in practical use due to time-consuming measuring method. We evaluated oxidized, human nonmercaptalbumin measured more quickly than ever by a novel method using anion-exchange HPLC. In 60 subjects taking a general health examination, mean serum human nonmercaptalbumin level was 25.1 ± 3.0% with no gender difference but positive correlation with age. There were no links between human nonmercaptalbumin and C-reactive protein, γ-glutamyltransferase or iron, reportedly associated with oxidative stress. Human nonmercaptalbumin correlated with systolic blood pressure, pulse pressure and body mass index among physical findings. Positive correlations were observed between human nonmercaptalbumin and AST, LDH, BUN, or creatinine, suggesting that oxidative stress may link with liver injury and renal function. Human nonmercaptalbumin correlated with uric acid in female but not in male, suggesting that higher uric acid levels may be associated with increased oxidative stress only in female. As another gender difference, white blood cell counts correlated with human nonmercaptalbumin in female, while the parameters for red blood cells correlated with human nonmercaptalbumin in male. In conclusion, serum human nonmercaptalbumin level in healthy subjects was approximately 25% as previously reported. Oxidative stress may be closely associated with hypertension, obesity, liver injury, renal function, and anemia.


Journal of medical technology | 2014

Effectiveness and problem of the blood transfusion management system in the operating room

Naomi Watanabe; Shinji Sone; Hiromitsu Yokota; Hirokazu Tsuno; Yutaka Yatomi; Koki Takahashi

備から輸血が実施される全過程において,過誤は許 されない.輸血に関する過誤は,重大なインシデン トやアクシデントにつながり,不適合輸血の原因の 過半数は,患者や輸血用血液の取り違いである.当 院では,年間 10,000 症例の手術が行われており,そ の約 30%で輸血用血液が準備されている.病棟・外 来での輸血の実施は,輸血輸液照合システムを用い て,リストバンドで患者を同定して,輸血用血液の 製造番号などを読込み照合確認後,輸血を実施する 手順で過誤防止に努めている.しかし,手術室への 輸血照合システムの導入は遅れていた. 手術で使用予定の血液は手術当日中輸血部で確保 され,必要になった時に,従来は麻酔医が手書きの 依頼票を輸血部に搬送して,輸血部から血液を供給 していた.手術室に供給された血液は,目視照合後 に輸血を実施していた.手書きの依頼票の患者 ID・ 氏名などは,目視で確認するため同姓や似た氏名,読 みづらい文字では読み違えがあった.また,輸血用 血液の供給依頼数や追加の準備単位数が多い長時間 原 著


The Japanese Journal of SURGICAL METABOLISM and NUTRITION | 2017

Are Albumin Products Appropriately being Used in Surgical Patients

Kazuhiko Fukatsu; S. Murakoshi; Shinji Sone; Hitoshi Okazaki; Seiichirou Kuroda; Hiroshi Suzuki; Hiroshi Yasuhara


The Japanese journal of clinical pathology | 2014

[Management of massive transfusion - the role of the blood transfusion service].

Shinji Sone; Tsuno H; Okazaki H


The Japanese journal of clinical pathology | 2013

Emergency drills and exercises to prepare the initial response and countermeasures for a disaster: an evacuation simulation for the hospital's outpatient blood collection room in the event of an earthquake

Makoto Kaneko; Hiroyuki Nakao; Kazuharu Morita; Shinji Sone; Akiko Masuda; Yutaka Yatomi

Collaboration


Dive into the Shinji Sone's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge